NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical Industries Ltd. (NYSE: TARO) securities between July 3, 2014 through September 9, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/taro-pharmaceutical-industries. There is no cost or obligation to you.
According to the complaint, during the Class Period Taro made false and/or misleading statements and/or failed to disclose material information, including that since 2014, Taro has violated federal antitrust laws by colluding with other pharmaceutical companies to keep the price of generic products artificially high.
On September 9, 2016, Taro disclosed the receipt of grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing. Then on October 17, 2016, an antitrust class action was filed against Taro and several other companies alleging they have engaged in the price-fixing of the generic drug Clobetasol since 2014.
If you suffered a loss in Taro you have until December 27, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/taro-pharmaceutical-industries.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.